What can functional brain imaging teach us about remission of type 2 diabetes?
fMRI
type 2 diabetes remission
weight loss
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
revised:
20
09
2023
received:
30
07
2023
accepted:
27
09
2023
medline:
13
11
2023
pubmed:
5
10
2023
entrez:
4
10
2023
Statut:
ppublish
Résumé
With a paradigm shift in attitudes towards type 2 diabetes (T2D), 'weight loss responsive' diabetes is now thought of as a curable disease state. As a result, national programmes are being orchestrated to induce T2D remission soon after diagnosis with aggressive dietary interventions-such as very low-calorie diets (VLCD). However, dietary interventions to achieve weight loss and diabetes remission lack the same long-term sustainability and cardiovascular risk reduction evidence as bariatric surgery. This review aims to explore how brain imaging has contributed to our understanding of human eating behaviours and how neural correlates are affected by T2D. We summarise functional MRI (fMRI) studies looking at human eating behaviour and obesity. We explore how these neural correlates are affected by insulin resistance and T2D itself as well as its different treatment approaches. Finally, we comment on the need for more personalised approaches to maintaining metabolic health and how fMRI studies may inform this. fMRI studies have helped to fashion our understanding of the neurobiology of human appetite and obesity. Improving our understanding of the neural implications of T2D that promote disadvantageous eating behaviours will enable prevention of disease as well as mitigation against a vicious cycle of metabolic dysfunction and associated cognitive complications.
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15235Subventions
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2023 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
Références
Diabetes UK. Number of people living with diabetes. Published 2023. Accessed July 28, 2023. https://www.diabetes.org.uk/about_us/news/number-people-living-diabetes-uk-tops-5-million-first-time#:~:text=Our%20new%20figures%20show%20that,2%20diabetes%20in%20the%20UK.
GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13-27. doi:10.1056/NEJMoa1614362
Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41(5):963-970. doi:10.2337/dc17-1962
Institute for Government (UK). Tackling Obesity. 2023. Accessed July 28, 2023. https://www.instituteforgovernment.org.uk/sites/default/files/2023-04/tackling-obesity.pdf
Baker C. Obesity Stat. 2023 Accessed July 28, 2023. https://researchbriefings.files.parliament.uk/documents/SN03336/SN03336.pdf
Vosoughi K, Salman Roghani R, Camilleri M. Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis. Obes Med. 2022;35:100456. doi:10.1016/j.obmed.2022.100456
Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous Semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619
White GE, Shu I, Rometo D, Arnold J, Korytkowski M, Luo J. Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: a retrospective cohort study. Obesity. 2023;31(2):537-544. doi:10.1002/oby.23622
Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402:613-626. doi:10.1016/S0140-6736(23)01200-X
Uzoigwe C, Noone J, Liang Y, Ali SN, Gamble C. Increased healthcare resource use and costs after discontinuation of liraglutide in patients with type 2 diabetes from a commercial- and Medicaid-insured claims database. Diabetes Ther. 2022;13(11-12):1861-1874. doi:10.1007/s13300-022-01322-z
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-Centre, randomised controlled trial. Lancet. 2015;386(9997):964-973. doi:10.1016/S0140-6736(15)00075-6
Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297-2304. doi:10.1001/jama.2014.5988
Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541-551. doi:10.1016/S0140-6736(17)33102-1
Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-1486. doi:10.2337/dc10-2415
Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, et al. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. Cell Metab. 2018;28(4):547-556.e3. doi:10.1016/j.cmet.2018.07.003
Sood HS, Maruthappu M, Valabhji J. The National Diabetes Prevention Programme: a pathway for prevention and wellbeing. Br J Gen Pract. 2015;65(636):336-337. doi:10.3399/bjgp15X685537
NHS England. Diabetes Remission. Accessed July 28, 2023. https://www.england.nhs.uk/diabetes/treatment-care/diabetes-remission/
Valabhji J, Barron E, Bradley D, et al. Early outcomes from the English National Health Service Diabetes Prevention Programme. Diabetes Care. 2020;43(1):152-160. doi:10.2337/dc19-1425
Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7(5):344-355. doi:10.1016/S2213-8587(19)30068-3
Courcoulas AP, Gallagher JW, Neiberg RH, et al. Bariatric surgery vs lifestyle intervention for diabetes treatment: 5-year outcomes from a randomized trial. J Clin Endocrinol Metab. 2020;105(3):866-876. doi:10.1210/clinem/dgaa006
Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. doi:10.1056/NEJMoa1105816
Churuangsuk C, Hall J, Reynolds A, Griffin SJ, Combet E, Lean MEJ. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia. 2022;65(1):14-36. doi:10.1007/s00125-021-05577-2
van der Laan LN, de Ridder DTD, Viergever MA, Smeets PAM. The first taste is always with the eyes: a meta-analysis on the neural correlates of processing visual food cues. Neuroimage. 2011;55(1):296-303. doi:10.1016/j.neuroimage.2010.11.055
Chaudhri OB, Salem V, Murphy KG, Bloom SR. Gastrointestinal satiety signals. Annu Rev Physiol. 2008;70(1):239-255. doi:10.1146/annurev.physiol.70.113006.100506
Batterham RL, ffytche DH, Rosenthal JM, et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature. 2007;450(7166):106-109. doi:10.1038/nature06212
Hinkle W, Cordell M, Leibel R, Rosenbaum M, Hirsch J. Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans. PloS One. 2013;8(3):e59114. doi:10.1371/journal.pone.0059114
Killgore WDS, Schwab ZJ, Weber M, et al. Daytime sleepiness affects prefrontal regulation of food intake. Neuroimage. 2013;71:216-223. doi:10.1016/j.neuroimage.2013.01.018
Brown CA, Schmitt FA, Smith CD, Gold BT. Distinct patterns of default mode and executive control network circuitry contribute to present and future executive function in older adults. Neuroimage. 2019;195:320-332. doi:10.1016/j.neuroimage.2019.03.073
Hare TA, Camerer CF, Rangel A. Self-control in decision-making involves modulation of the vmPFC valuation system. Science. 2009;324(5927):646-648. doi:10.1126/science.1168450
Yang Y, Shields GS, Guo C, Liu Y. Executive function performance in obesity and overweight individuals: a meta-analysis and review. Neurosci Biobehav Rev. 2018;84:225-244. doi:10.1016/j.neubiorev.2017.11.020
Cornier MA, Salzberg AK, Endly DC, Bessesen DH, Rojas DC, Tregellas JR. The effects of overfeeding on the neuronal response to visual food cues in thin and reduced-obese individuals. PloS One. 2009;4(7):e6310. doi:10.1371/journal.pone.0006310
Goldstone AP, Prechtl de Hernandez CG, Beaver JD, et al. Fasting biases brain reward systems towards high-calorie foods. Eur J Neurosci. 2009;30(8):1625-1635. doi:10.1111/j.1460-9568.2009.06949.x
Demos KE, Heatherton TF, Kelley WM. Individual differences in nucleus Accumbens activity to food and sexual images predict weight gain and sexual behavior. J Neurosci. 2012;32:5549-5552. doi:10.1523/JNEUROSCI.5958-11.2012
Rothemund Y, Preuschhof C, Bohner G, et al. Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals. Neuroimage. 2007;37:410-421. doi:10.1016/j.neuroimage.2007.05.008
Macpherson H, Formica M, Harris E, Daly RM. Brain functional alterations in type 2 diabetes - a systematic review of fMRI studies. Front Neuroendocrinol. 2017;47:34-46. doi:10.1016/j.yfrne.2017.07.001
Wu M, Brockmeyer T, Hartmann M, Skunde M, Herzog W, Friederich HC. Reward-related decision making in eating and weight disorders: a systematic review and meta-analysis of the evidence from neuropsychological studies. Neurosci Biobehav Rev. 2016;61:177-196. doi:10.1016/j.neubiorev.2015.11.017
Bae JH, Choi HJ, Cho KIK, Kim LK, Kwon JS, Cho YM. Glucagon-like Peptide-1 receptor agonist differentially affects brain activation in response to visual food cues in Lean and obese individuals with type 2 diabetes mellitus. Diabetes Metab J. 2020;44(2):248-259. doi:10.4093/dmj.2019.0018
van Bloemendaal L, IJzerman RG, ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186-4196. doi:10.2337/db14-0849
Ryan JP, Karim HT, Aizenstein HJ, Helbling NL, Toledo FGS. Insulin sensitivity predicts brain network connectivity following a meal. Neuroimage. 2018;171:268-276. doi:10.1016/j.neuroimage.2018.01.024
Kullmann S, Heni M, Veit R, et al. Selective insulin resistance in homeostatic and cognitive control brain areas in overweight and obese adults. Diabetes Care. 2015;38(6):1044-1050. doi:10.2337/dc14-2319
Kullmann S, Heni M, Veit R, et al. Intranasal insulin enhances brain functional connectivity mediating the relationship between adiposity and subjective feeling of hunger. Sci Rep. 2017;7(1):1627. doi:10.1038/s41598-017-01907-w
Frank S, Heinze JM, Fritsche A, et al. Neuronal food reward activity in patients with type 2 diabetes with improved glycemic control after bariatric surgery. Diabetes Care. 2016;39(8):1311-1317. doi:10.2337/dc16-0094
Scholtz S, Miras AD, Chhina N, et al. Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding. Gut. 2014;63(6):891-902. doi:10.1136/gutjnl-2013-305008
Baboumian S, Pantazatos SP, Kothari S, McGinty J, Holst J, Geliebter A. Functional magnetic resonance imaging (fMRI) of neural responses to visual and auditory food stimuli pre and post Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). Neuroscience. 2019;409:290-298. doi:10.1016/j.neuroscience.2019.01.061
Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N. Ghrelin, CCK, GLP-1, and PYY(3-36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev. 2017;97(1):411-463. doi:10.1152/physrev.00031.2014
De Silva A, Salem V, Long CJ, et al. The gut hormones PYY3-36 and GLP-17-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab. 2011;14(5):700-706. doi:10.1016/j.cmet.2011.09.010
ten Kulve JS, Veltman DJ, van Bloemendaal L, et al. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia. 2015;58(12):2688-2698. doi:10.1007/s00125-015-3754-x
ten Kulve JS, Veltman DJ, van Bloemendaal L, et al. Liraglutide reduces CNS activation in response to visual food cues only after short-term treatment in patients with type 2 diabetes. Diabetes Care. 2016;39(2):214-221. doi:10.2337/dc15-0772
van Ruiten CC, ten Kulve JS, van Bloemendaal L, Nieuwdorp M, Veltman DJ, IJzerman RG. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial. Psychoneuroendocrinology. 2022;137:105667. doi:10.1016/j.psyneuen.2022.105667
Farr OM, Upadhyay J, Rutagengwa C, et al. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: implications for plateauing weight loss in response to anti-obesity therapies. Diabetes Obes Metab. 2019;21(11):2459-2464. doi:10.1111/dom.13827
van Ruiten CC, Veltman DJ, Wijdeveld M, et al. Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2022;24(8):1588-1597. doi:10.1111/dom.14732
Salem V, Demetriou L, Behary P, et al. Weight loss by low-calorie diet versus gastric bypass surgery in people with diabetes results in divergent brain activation patterns: a functional MRI study. Diabetes Care. 2021;44(8):1842-1851. doi:10.2337/dc20-2641